External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Robust Results Once Again: Lupin reported another strong quarter, driven by outperformance in the US business led by high-margin complex generics, notably gTolvaptan, Mirabegron, and Risperdal Consta, along with robust growth across emerging markets.</li><li>Strong gross margin expansion translated into a sharp EBITDA and PAT beat.</li><li>Revenue stood at Rs 7,168 Cr (+24% YoY), well above estimates, while EBITDA increased 67% YoY to Rs 2,262 Cr, with margins at 31.6%.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Robust Results Once Again: Lupin reported another strong quarter, driven by outperformance in the US business led by high-margin complex generics, notably gTolvaptan, Mirabegron, and Risperdal Consta, along with robust growth across emerging markets.Strong gross margin expansion translated into a sharp EBITDA and PAT beat.Revenue stood at Rs 7,168 Cr (+24% YoY), well above estimates, while EBITDA increased 67% YoY to Rs 2,262 Cr, with margins at 31.6%.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Lupin Ltd - Building a Durable Growth Engine